Benova Mouth Rinse Study Shows Significant Reduction in Inflammatory Marker TNF-Alpha
TL;DR
The Benova Mouth Rinse System offers a competitive edge by reducing TNFα by 17% in 2 minutes, providing fast relief for oral inflammation without prescriptions.
The study demonstrates the Benova Mouth Rinse System's mechanism reduces TNFα in inflamed oral mucosa, offering a scientific approach to managing oral mucositis.
Benova's innovation improves quality of life for millions suffering from oral mucositis and canker sores by accelerating healing and reducing pain without harsh medications.
Discover how Benova's mouth rinse quickly cuts inflammation markers, offering a glimpse into future wound care solutions at the DLS Conference.
Found this article helpful?
Share it with your network and spread the knowledge!
The Benova Mouth Rinse System has demonstrated a significant reduction in the inflammatory marker tumor necrosis factor-alpha (TNFα), according to a study presented at the 2025 Diabetic Limb Salvage (DLS) Conference. The research, conducted at the University of Alabama Capstone College of Nursing, showed a 17% decrease in TNFα levels within just 2 minutes of application, highlighting the system's potential to alleviate pain and support healing in patients with inflammatory oral conditions.
Oral mucositis affects approximately 51% of cancer patients undergoing chemotherapy, while recurrent aphthous stomatitis (RAS), or canker sores, is found in 25% of the general population. TNFα plays a critical role in driving the inflammatory responses that lead to cell damage and death in these conditions. The Benova Mouth Rinse System's ability to rapidly reduce TNFα levels without the use of lidocaine, steroids, or prescription medications represents a promising advancement in the treatment of these painful conditions.
Dr. Daniel J. Gibson, who specializes in research on tissue fate determination, presented the findings at the DLS Conference. He emphasized the significance of the results, stating, 'These results reflect Benova's potential to relieve pain and support healing through targeted cytokine reduction.' Bill Kling, co-founder of Benova, also expressed excitement over the study's outcomes, noting the correlation between the laboratory findings and positive patient feedback regarding pain relief and healing.
The Diabetic Limb Salvage Conference serves as a key platform for sharing innovations in wound care and tissue regeneration, attracting specialists from various medical fields. The Benova Mouth Rinse System's introduction at this event underscores its relevance and potential impact on patient care, particularly for those dealing with diabetic foot and limb wounds, as well as oral inflammatory conditions.
For further details on the study's scientific rationale and findings, interested parties can access the full poster presentation. The Benova Mouth Rinse System continues to gain recognition among healthcare professionals, including oncologists, oncology nurses, dentists, and periodontists, for its effectiveness in providing immediate relief from mouth sores without the need for numbing agents or prescriptions.
Curated from 24-7 Press Release
